NCT05498103Active, not recruitingPhase 4
Use of Methazolamide to Lower Intraocular Pressure
Source: ClinicalTrials.gov · Last updated 6 Feb 2024
Brief summary (registry, in English)
The purpose of this study is to evaluate the effect of methazolamide, 25 mg or 50 mg tablets once a day for a week than twice a day for a week, on lowering intraocular pressure and the safety of methazolamide.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 9 Aug 2022
- Start date
- 17 Feb 2023
- Primary completion date
- 14 Sept 2023
- Lead sponsor
- University of Colorado, Denver
- Diseases
- Glaucoma
- NCT number
- NCT05498103
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 30
- From 17 Feb 2023 to the primary completion date, 14 Sept 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Glaucoma other than OAG
- Severe or end-stage glaucoma (cup to disc ratio \>0.8 or Mean Deviation on Visual Field worse than -12)
- Pregnant or breast-feeding women
Who the study is looking for
- Males and females between 50 and 90 years old
- Current diagnosis of open angle glaucoma (OAG) in both eyes
- Ability to read and write in English
Age in the registry: 50 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sue Anschutz-Rodgers Eye Center Coordinator of this site? Confirm its status | Aurora | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.